Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors
暂无分享,去创建一个
[1] T. Andersson,et al. The effect of oral omeprazole on the disposition of lignocaine , 1994, Anaesthesia.
[2] D. Nebert,et al. Cytochrome P450: evolution and functional diversity. , 1994, Progress in liver diseases.
[3] J. Connell,et al. Dose related in vitro effects of ranitidine and cimetidine on basal and ACTH-stimulated steroidogenesis. , 1986, Gut.
[4] T. Andersson,et al. Pharmacokinetics of [14C] omeprazole in patients with impaired renal function , 1986, Clinical pharmacology and therapeutics.
[5] L. Wienkers,et al. Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. , 1994, Drug metabolism and disposition: the biological fate of chemicals.
[6] G R Wilkinson,et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.
[7] P. Beaune,et al. The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. , 1989, British journal of clinical pharmacology.
[8] D. Colin-Jones. Safety of lansoprazole , 1993, British journal of clinical practice. Supplement.
[9] J. Miners,et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. , 1993, British journal of clinical pharmacology.
[10] L. Bertilsson,et al. Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S‐mephenytoin, but not debrisoquin, hydroxylation phenotype , 1989, Clinical pharmacology and therapeutics.
[11] P. Höglund,et al. Stereoselective Interaction of Omeprazole with Warfarin in Healthy Men , 1989, Therapeutic drug monitoring.
[12] M. O'Mahony,et al. Age, environmental factors and drug metabolism. , 1994, Pharmacology & therapeutics.
[13] T. Sullivan,et al. Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity. , 1993, British journal of clinical pharmacology.
[14] T. Andersson,et al. A study of the interaction between omeprazole and cyclosporine in renal transplant patients. , 1993, British journal of clinical pharmacology.
[15] A. Blum,et al. Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers. , 1994, Scandinavian journal of gastroenterology.
[16] J. Goldstein,et al. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. , 1993, Molecular pharmacology.
[17] A. Richens,et al. Oral phenytoin pharmacokinetics during omeprazole therapy. , 1987, British journal of clinical pharmacology.
[18] A. Parkinson,et al. Omeprazole and the induction of human cytochrome P-450: a response to concerns about potential adverse effects. , 1991, Gastroenterology.
[19] R. Bergstrand,et al. Omeprazole treatment does not affect the metabolism of caffeine. , 1991, Gastroenterology.
[20] R. Pounder,et al. Twenty‐four‐hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole , 1987, Alimentary pharmacology & therapeutics.
[21] C. K. Stead,et al. Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole , 1991, Alimentary pharmacology & therapeutics.
[22] J. Miners,et al. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. , 1994, British journal of clinical pharmacology.
[23] D. Kroetz,et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. , 1994, Biochemical pharmacology.
[24] A. Conney,et al. Stimulatory effect of brussels sprouts and cabbage on human drug metabolism , 1979, Clinical pharmacology and therapeutics.
[25] R. Kato,et al. Hepatic microsomal tolbutamide hydroxylation in Japanese: in vitro evidence for rapid and slow metabolizers. , 1993, Pharmacogenetics.
[26] S. Meuwissen,et al. Lack of effect of antacids on plasma concentrations of omeprazole given as enteric-coated granules. , 1987, British journal of clinical pharmacology.
[27] A. Conney,et al. Effect of cigarette smoking on phenacetin metabolism , 1974, Clinical pharmacology and therapeutics.
[28] R. Gugler,et al. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. , 1985, Gastroenterology.
[29] T. Kamataki,et al. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. , 1993, The Journal of pharmacology and experimental therapeutics.
[30] H. Wynne,et al. Hepatic drug clearance: the effect of age using indocyanine green as a model compound. , 1990, British journal of clinical pharmacology.
[31] C. Wolf,et al. Differences in the cytochrome P-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17 alpha-ethinyloestradiol. Relative activities of rat and human liver enzymes. , 1990, The Biochemical journal.
[32] A. Cohen,et al. Influence of gastric acidity on the bioavailability of digoxin. , 1991, Annals of internal medicine.
[33] D. V. van Thiel,et al. Hypothalamic-pituitary-gonadal dysfunction in men using cimetidine. , 1979, The New England journal of medicine.
[34] J. Miners,et al. Co-regulation of phenytoin and tolbutamide metabolism in humans. , 1992, British journal of clinical pharmacology.
[35] P. Lindberg,et al. The mechanism of action of the gastric acid secretion inhibitor omeprazole. , 1986, Journal of medicinal chemistry.
[36] S. Landahl,et al. Renal function in an elderly population. A study of S-creatinine, 51Cr-EDTA clearance, endogenous creatinine clearance and maximal tubular water reabsorption. , 1986, Scandinavian journal of clinical and laboratory investigation.
[37] H. Ostensen,et al. The incidence of peptic ulcer disease related to occupation in the northern part of Norway. A prospective epidemiological and radiological study. , 1985, Scandinavian journal of gastroenterology.
[38] J. Brockmöller,et al. Assessment of Liver Metabolic Function , 1994, Clinical pharmacokinetics.
[39] T. Andersson,et al. Bioavailability of Omeprazole as Enteric Coated (EC) Granules in Conjunction with Food on the First and Seventh Days of Treatment , 1990 .
[40] K. Brøsen,et al. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. , 1990, British journal of clinical pharmacology.
[41] J. Miners,et al. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. , 1994, British journal of clinical pharmacology.
[42] T. Andersson. Omeprazole Drug Interaction Studies , 1991, Clinical pharmacokinetics.
[43] K. Anderson,et al. Enhanced phenacetin metabolism in human subjects fed charcoal‐broiled beef , 1976, Clinical pharmacology and therapeutics.
[44] F. Guengerich,et al. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. , 1991, Chemical research in toxicology.
[45] J. Miners,et al. Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies. , 1988, Biochemical pharmacology.
[46] M. J. Coon,et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. , 1993, DNA and cell biology.
[47] U. Klotz,et al. Lansoprazole does not affect the bioavailability of oral contraceptives. , 1994, British journal of clinical pharmacology.
[48] G. Ekenved,et al. Bioavailability studies on a buffered acetylsalicylic acid preparation. , 1975, Acta pharmaceutica Suecica.
[49] T. Andersson,et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. , 1991, British journal of clinical pharmacology.
[50] M. Lennard,et al. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. , 1982, British journal of clinical pharmacology.
[51] P. Lindberg,et al. Chemical Reactions of Omeprazole and Omeprazole Analogues. I. A Survey of the Chemical Transformations of Omeprazole and its Analogues. , 1989 .
[52] J. Brockmöller,et al. Increase of cytochrome P450IA2 activity by omeprazole: Evidence by the 13C‐[N‐3‐methyl]‐caffeine breath test in poor and extensive metabolizers of S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.
[53] E. Perucca,et al. Omeprazole Does Not Enhance the Metabolism of Phenacetin, a Marker of CYP1A2 Activity, in Healthy Volunteers , 1994, Therapeutic drug monitoring.
[54] W. Wurst,et al. Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. , 1991, International journal of clinical pharmacology, therapy, and toxicology.
[55] T. Andersson,et al. The Pharmacokinetics of Omeprazole in Humans—A Study of Single Intravenous and Oral Doses , 1990, Therapeutic drug monitoring.
[56] F. Guengerich,et al. Oxidation of quinidine by human liver cytochrome P-450. , 1986, Molecular pharmacology.
[57] E. Greisheimer. Physiology of the alimentary tract. , 1952, Journal of the American Medical Women's Association.
[58] Yuan Zhang,et al. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. , 1992, Pharmacogenetics.
[59] A. Pilbrant,et al. Development of an oral formulation of omeprazole. , 1985, Scandinavian journal of gastroenterology. Supplement.
[60] F. Guengerich,et al. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. , 1991, The Journal of pharmacology and experimental therapeutics.
[61] C. Bonfils,et al. Oxidative metabolism of lansoprazole by human liver cytochromes P450. , 1995, Molecular pharmacology.
[62] H. Wynne,et al. Age-Related Changes in Hepatic Function , 1992, Drugs & aging.
[63] M. Regazzi,et al. Pharmacokinetics of omeprazole in cirrhotic patients. , 1991, Arzneimittel-Forschung.
[64] W. Wurst,et al. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. , 1995, International journal of clinical pharmacology and therapeutics.
[65] W. Wurst,et al. Lack of pantoprazole drug interactions in man. , 1994, International journal of clinical pharmacology and therapeutics.
[66] T. Andersson,et al. Pharmacokinetic Study of Omeprazole in Elderly Healthy Volunteers , 1992, Clinical pharmacokinetics.
[67] T. Andersson,et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. , 1992, British journal of clinical pharmacology.
[68] B K Tang,et al. Biotransformation of caffeine by microsomes from human liver. Kinetics and inhibition studies. , 1987, Biochemical pharmacology.
[69] S. Toon,et al. Effects of Cimetidine, Ranitidine and Omeprazole on Tolbutamide Pharmacokinetics , 1995 .
[70] R. Gugler,et al. Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. , 1987, Pharmacology & therapeutics.
[71] I. Roots,et al. Specific and dose‐dependent enzyme induction by omeprazole in human beings , 1994, Hepatology.
[72] R. Schall,et al. Effect of Pantoprazole on Ovulation Suppression by a Low-Dose Hormonal Contraceptive , 1995 .
[73] E. Ganse,et al. Influence of lansoprazole treatment on diazepam plasma concentrations , 1992, Clinical pharmacology and therapeutics.
[74] R. Bergstrand,et al. Decreased Oral Bioavailability of Lansoprazole in Healthy Volunteers when Given with a Standardised Breakfast , 1995 .
[75] B. Flouvat,et al. The effect of food and antacids on lansoprazole absorption and disposition. , 1991, European journal of drug metabolism and pharmacokinetics.
[76] B. Flouvat,et al. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. , 1993, British journal of clinical pharmacology.
[77] R. Schall,et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. , 1995, British journal of clinical pharmacology.
[78] J. Michnovicz,et al. Omeprazole fails to alter the cytochrome P450-dependent 2-hydroxylation of estradiol in male volunteers. , 1993, Pharmacology.
[79] J. Miners,et al. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. , 1991, British journal of clinical pharmacology.
[80] G. Beastall,et al. Inhibition by omeprazole of adrenocortical response to ACTH: clinical studies and experiments on bovine adrenal cortex in vitro. , 1986, Clinical science.
[81] D. Stevens,et al. Ketoconazole blocks adrenal steroid synthesis. , 1982, Annals of internal medicine.
[82] L. Bertilsson,et al. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. , 1990, Therapeutic drug monitoring.
[83] Jerome J. Schentag,et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability , 1991, Antimicrobial Agents and Chemotherapy.
[84] R. Edwards,et al. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. , 1988, British journal of clinical pharmacology.
[85] G. Sachs,et al. Continuing development of acid pump inhibitors: site of action of pantoprazole. , 1994, Alimentary pharmacology & therapeutics.
[86] J. Miners,et al. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. , 1994, British journal of clinical pharmacology.
[87] H. Balks,et al. The effects of lansoprazole, 30 or 60 mg daily, on intragastric pH and on endocrine function in healthy volunteers , 1993, Alimentary pharmacology & therapeutics.
[88] T. Andersson,et al. No Influence of Single Intravenous Doses of Omeprazole on Theophylline Elimination Kinetics , 1992, Journal of clinical pharmacology.
[89] G. Tucker,et al. The interaction of proton pump inhibitors with cytochromes P450. , 1994, Alimentary pharmacology & therapeutics.
[90] L. Benet,et al. Pharmacokinetics‐‐a relevant factor for the choice of a drug? , 1994, Alimentary Pharmacology and Therapeutics.
[91] P. Beaune,et al. Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. , 1992, Biochemical pharmacology.
[92] T. Andersson,et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. , 1994, Therapeutic drug monitoring.
[93] T. Adrian,et al. Effect of single dose of omeprazole on the gastrointestinal peptide response to food. , 1984, Hepato-gastroenterology.
[94] K. Chiba,et al. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population. , 1992, The Journal of pharmacology and experimental therapeutics.
[95] P. Höglund,et al. No effect of omeprazole-induced hypoacidity on the bioavailability of amoxycillin or bacampicillin. , 1989, Scandinavian journal of infectious diseases.
[96] S. Kitareewan,et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. , 1994, Biochemistry.
[97] L. Kaminsky,et al. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. , 1995, Biochemical pharmacology.
[98] G. Sachs,et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+) ATPase , 1981, Nature.
[99] U. Haglund,et al. Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man. , 1983, Gut.
[100] U. Meyer,et al. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4 , 1989, Clinical pharmacology and therapeutics.
[101] A. Gent,et al. Adhesive and hydrophobic properties of Escherichia coli from the rectal mucosa of patients with ulcerative colitis. , 1993, Gut.
[102] M. Mayersohn. Chapter 8 Physiological Factors that Modify Systemic Drug Availability and Pharmacologic Response in Clinical Practice , 1978 .
[103] O. Garden,et al. The anti‐secretory effect and pharmacokinetics of omeprazole in chronic liver disease , 1988, Alimentary pharmacology & therapeutics.
[104] B. Brodie,et al. Principles and perspectives in drug bioavailability , 1979 .
[105] W. Londong. Effect of pantoprazole on 24‐h intragastric pH and serum gastrin in humans. , 1994, Alimentary pharmacology & therapeutics.
[106] T. Andersson,et al. Pharmacokinetics of [14C]Omeprazole in Patients with Liver Cirrhosis , 1993, Clinical pharmacokinetics.
[107] M. Lai,et al. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6 , 1993, Clinical pharmacology and therapeutics.
[108] P. Lundborg,et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole , 1990, Clinical pharmacology and therapeutics.
[109] O. Mcbride,et al. Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. , 1988, DNA.
[110] P. Guzelian,et al. Characterization of human liver cytochromes P-450 involved in theophylline metabolism. , 1992, Drug metabolism and disposition: the biological fate of chemicals.
[111] R. Luehmann,et al. Effects of pantoprazole on endocrine function in healthy male volunteers , 1994, Alimentary pharmacology & therapeutics.
[112] M. Relling,et al. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. , 1990, The Journal of pharmacology and experimental therapeutics.
[113] E. D. Jacobson,et al. Histamine H1- and H2-receptor vasodilation of canine intestinal circulation. , 1977, The American journal of physiology.
[114] K. Tolman,et al. Effect of Lansoprazole on Male Hormone Function , 1994 .
[115] C. Regårdh,et al. Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. , 1985, Scandinavian journal of gastroenterology. Supplement.
[116] R. Branch,et al. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities , 1989, Clinical pharmacology and therapeutics.
[117] G. Sachs,et al. The continuing development of proton pump inhibitors with particular reference to pantoprazole , 1995, Alimentary pharmacology & therapeutics.
[118] Immediate Effect of Omeprazole and Cimetidine on Apparent Liver Blood Flow in Man , 1986 .
[119] C. Funck-Brentano,et al. Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans , 1992, Clinical pharmacology and therapeutics.
[120] T. Andersson,et al. A Study of the Interaction Between Omeprazole and Phenytoin in Epileptic Patients , 1990, Therapeutic drug monitoring.
[121] J. Kolars,et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. , 1994, Drug metabolism and disposition: the biological fate of chemicals.
[122] R. Schall,et al. No influence of pantoprazole on the pharmacokinetics of phenytoin. , 1995, International journal of clinical pharmacology and therapeutics.
[123] G. Granneman,et al. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. , 1993, British journal of clinical pharmacology.
[124] Ajit Kumar,et al. Effect of Multiple Dose Omeprazole on the Pharmacokinetics of Carbamazepine , 1994 .
[125] F. Sundler,et al. Lansoprazole and omeprazole have similar effects on plasma gastrin levels, enterochromaffin-like cells, gastrin cells and somatostatin cells in the rat stomach. , 1992, Digestion.
[126] L. Benet,et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine , 1995, Clinical pharmacology and therapeutics.
[127] J. Schuetz,et al. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. , 1994, Pharmacogenetics.
[128] T. Kronbach,et al. Cyclosporine metabolism in human liver: Identification of a cytochrome P‐450III gene family as the major cyclosporine‐metabolizing enzyme explains interactions of cyclosporine with other drugs , 1988, Clinical pharmacology and therapeutics.
[129] L. Bertilsson,et al. No Effect on Plasma Carbamazepine Concentration with Concomitant Omeprazole Treatment , 1995 .
[130] J. Kolars,et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.